Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-06-15
1996-11-05
Cintins, Marianne M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3144
Patent
active
055718272
ABSTRACT:
Methods and compositions are disclosed utilizing the optically pure S(-) isomer of nitrendipine. This compound is a potent drug for the treatment of hypertension while avoiding the concomitant liability of adverse effects associated with the administration of the racemic mixture of nitrendipine. The S(-) isomer of nitrendipine is also useful for the treatment of angina and such other conditions as may be related to the activity of S(-) nitrendipine as a calcium channel antagonist without the concomitant liability of adverse effects associated with the racemic mixture of nitrendipine.
REFERENCES:
patent: 3799934 (1974-03-01), Meyer et al.
patent: 3799936 (1974-03-01), Meyer et al.
patent: 3932645 (1976-01-01), Meyer et al.
patent: 3932646 (1976-01-01), Meyer et al.
patent: 4145432 (1979-03-01), Sato
patent: 4582840 (1986-04-01), Garthoff et al.
patent: 4707486 (1987-11-01), Flockerzi et al.
patent: 4724141 (1988-02-01), Schmidt et al.
patent: 4975440 (1990-12-01), Flockerzi et al.
patent: 5039674 (1991-08-01), Fujikena et al.
patent: 5051433 (1991-09-01), Stoltefuss et al.
Shibanuma, T. et al., "Synthesis of Optically Active 2-(N-Benzyl-N-methylamino) ethyl Methyl 2,6-Dimethy-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate (Nicardipine)," Chem. Pharm. Bull., 28(9):2809-2812 (1980).
Chemical Abstract, 98:317g (1983).
Thomas, G. et al., "Action of dihydropyridine Ca-channel-modulators on isolated heart preparations," Cardiologia, 32(4):1047-1052 (1987).
Maan, A. C. et al. "Analysis of the Properties of Binding of Calcium-Channel Activators and Inhibitors to Dihydropyridine Receptors in Chick Heart Membranes," Circulation Research, 61(3):379-388, 1987.
Rampe, D. et al., "Comparative aspects and temperature dependence of [.sup.3 H]1,4-dihydropyridine Ca.sup.2+ channel antagonist and activator binding to neuronal and muscle membrane," Canadian Journal Physiology Pharmacology, 65(7):1452-1460 (1987).
Yatani, A. "Effects of dihydropyridine calcium channel modulators on carciac sodium channels," Am. J. Physiol. 254 (Heart Circ. Pyysiol. 23) H140-H147 (1989).
Soons, P. A. et al., "Oral absorption profile of nitrendipine in healthy subjects: a kinetic and dynamic study," Br. J. Clin. Pharm. 27:179-189 (1989).
Saha, J. K. et al., "Analysis of the effects of (-) and (+) isomers of the 1,4-dihydropyridine calcium channel agonist BAY k 8644 on postrest potentiation in the canine ventricular muscle," Canadian Journal Physiology & Pharmacology, 67(7):788-794 (1989).
M orike, K. et al., "221 H amodynamische und biochemische Wirkungen der Nitrendipin-Enantiomere," Klin Wochenschr 67 (Suppl. XVI): 120-121 (1989).
Mikus, G. et al., "Pharmacokinetics, Hemodynamic and Biochemical Effects of the Nitrendipine Enantiomers," Euv. J. Clin. Pharmac. 36(Suppl) A179 (1989).
Soons, P. A. et al., "Stereoselective kinets of Felopine and Nitrendipine in Man," Clin. Pharmacol. Ther. p. 158 Abstract No. PII-40 (1990).
Soons, P. A. et al., "Enantioselective determination of felodipine and other chiral dihydropyridine calcium entry blockers in human plasma," Journal of Chromatography Biomedical Applications, 528:343-356 (1990).
Eltze, M. et al. "Stereoselective Inhibition of Thromboxane-induced Coronary Vasoconstriction by 1,4-Dihydropyridine Calcium Channel Antagonists," Chirality 2:233-240 (1990).
Okamoto, Y. et al. "Optical resolution of dihydropyridine enantiomers by high-performance liquid chromatography using phenylcarbamates of polysaccharides as chiral stationary phase," Journal of Chromatography, 513:375-378 (1990).
O'Neill, S. K. et al., "Comparative Studies With Enantiomers of Dihydropyridine Ligands Suggests That There Are Multiple Binding Sites Associated With The Calcium Channel," Proc. West. Pharmacol. Soc., 33:235-241 (1990).
Soons, P. A. et al., "Stereoselective pharmcokinetics of oral and intravenous nitrendipine in healthy male subjects," Br. J. Clin. Pharmac., 32, 11-16 (1991).
Soons, P. A. et al., "Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans," Pharmacokinetics and Drug Disposition, 50(4):394-403 (1991).
Mast, V. et al. "Use of pesudoracemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers," Br. J. Clin. Pharmac., 33:51-59 (1992).
Zernig and Glossman, "A novel 1,4-dihydropyridine-binding site on mitochondrial membranes from guinea-pig heart, liver and kidney", Biochem. J 253: 49-58 (1988).
Barberich Timothy J.
Young James W.
Cintins Marianne M.
Jarvis William R. A.
Sepracor Inc.
LandOfFree
Methods and compositions for treating hypertension, angina and o does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treating hypertension, angina and o, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating hypertension, angina and o will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2015421